Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbott Laboratories (ABT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,915,728
  • Shares Outstanding, K 1,756,333
  • Annual Sales, $ 30,578 M
  • Annual Income, $ 2,368 M
  • 36-Month Beta 1.14
  • Price/Sales 4.25
  • Price/Cash Flow 17.77
  • Price/Book 4.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.61
  • Number of Estimates 8
  • High Estimate 0.62
  • Low Estimate 0.61
  • Prior Year 0.59
  • Growth Rate Est. (year over year) +3.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.80 +9.37%
on 01/29/19
75.40 -0.20%
on 02/15/19
+4.78 (+6.78%)
since 01/15/19
3-Month
65.44 +14.99%
on 12/24/18
75.40 -0.20%
on 02/15/19
+4.52 (+6.39%)
since 11/15/18
52-Week
56.81 +32.46%
on 05/03/18
75.40 -0.20%
on 02/15/19
+15.75 (+26.47%)
since 02/15/18

Most Recent Stories

More News
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

ABT : 75.25 (+1.73%)
AMED : 136.22 (-1.81%)
PEN : 155.57 (+1.32%)
CSII : 33.60 (+1.69%)
Branded Generics Market 2019 Global Analysis, Opportunities And Forecast To 2024

VRX.TO : 30.80 (-3.33%)
ABT : 75.25 (+1.73%)
NVS : 89.88 (+0.97%)
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

ABT : 75.25 (+1.73%)
JNJ : 136.38 (+1.54%)
GSK : 41.24 (+0.93%)
BMY : 51.67 (+1.65%)
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

ABT : 75.25 (+1.73%)
DGX : 87.81 (+2.70%)
ANGO : 23.46 (+1.34%)
CNMD : 71.94 (+1.27%)
Baxter's Acute Therapies Profile Strong, Competition Rife

Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

ABT : 75.25 (+1.73%)
SRDX : 56.81 (+5.73%)
BAX : 73.43 (+1.37%)
CSII : 33.60 (+1.69%)
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

Bio-Techne (TECH) sees increase in revenues across key segments.

TECH : 191.63 (+1.63%)
ABT : 75.25 (+1.73%)
ANGO : 23.46 (+1.34%)
CNMD : 71.94 (+1.27%)
Boston Scientific Benefits From New Buyouts & Product Launch

Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.

ABT : 75.25 (+1.73%)
AMED : 136.22 (-1.81%)
BSX : 40.01 (+0.23%)
PEN : 155.57 (+1.32%)
Here's Why Investors Should Retain AmerisourceBergen Stock

AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.

ABC : 86.66 (+0.24%)
ABT : 75.25 (+1.73%)
SRDX : 56.81 (+5.73%)
CSII : 33.60 (+1.69%)
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.

EW : 177.78 (+0.94%)
ABT : 75.25 (+1.73%)
AMED : 136.22 (-1.81%)
PEN : 155.57 (+1.32%)
Here's Why Investors Should Retain Accuray (ARAY) Stock Now

A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.

ABT : 75.25 (+1.73%)
SRDX : 56.81 (+5.73%)
ARAY : 4.93 (+2.49%)
CSII : 33.60 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ABT with:

Business Summary

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

See More

Key Turning Points

2nd Resistance Point 76.06
1st Resistance Point 75.66
Last Price 75.25
1st Support Level 74.59
2nd Support Level 73.92

See More

52-Week High 75.40
Last Price 75.25
Fibonacci 61.8% 68.30
Fibonacci 50% 66.11
Fibonacci 38.2% 63.91
52-Week Low 56.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar